Linked e-resources
Details
Table of Contents
Intro; Preface; Contents; Abbreviations; About the Editor; 1: Glucose Metabolism Imaging; 1.1 Glucose Metabolism; 1.1.1 Glucose Metabolism Pathway and Flux Analysis; 1.1.2 Biochemical of Glucose Metabolism; 1.1.3 Abnormal Glucose Metabolism and Related Diseases; 1.2 Glucose Metabolism and Tumor; 1.2.1 Cancer (Tumor Suppressor) Gene and Glucose Metabolism; 1.2.2 Glucose Enzyme and Tumor; 1.2.3 Glucose Metabolism and Targeted Therapy; 1.3 18F-FDG PET/CT Scanning; 1.3.1 Glucose and 18F-Fluorodeoxyglucose (18F-FDG); 1.3.2 18F-FDG PET/CT Scanning
1.3.3 Clinical Utility of 18F-FDG PET/CT ScanningReferences; 2: Clinical Utility of PET/CT in Breast Cancer Management and Targeted Therapy; 2.1 Introduction; 2.1.1 Epidemiology; 2.1.2 Molecular Subtypes and Gene Expression Tests in Breast Cancer; 2.1.3 Targeted Therapy for Breast Cancer; 2.1.3.1 Anti-HER2 Targeted Therapy; 2.1.3.2 Anti-angiogenic Targeted Therapy; 2.1.3.3 PI3K/AKT/mTOR Pathway Inhibitor; 2.1.3.4 Other Targeted Therapy; 2.2 Clinical Utility of 18F-FDG PET/CT in Breast Cancer; 2.2.1 The Heterogeneity and 18F-FDG Uptake in Breast Cancer
2.2.2 Detection and Differentiation of Primary Breast Cancer2.2.3 Initial Staging; 2.2.3.1 T Staging; 2.2.3.2 Axillary Lymph Node Staging; 2.2.3.3 Staging in Stage II-III Disease and Inflammatory Breast Cancer; 2.2.3.4 Distant Metastases of Breast Cancer; Skeleton Metastases; Extra-skeletal Metastases; 2.2.4 Response Assessment; 2.2.4.1 Early Response Assessment; 2.2.4.2 Post-therapy Evaluation; 2.2.5 Monitoring Recurrence; 2.2.6 Prognostic Assessment; 2.3 Clinical Application of 18F-Fluoroestradiol PET; 2.3.1 18F-FES Uptake and Tumor ER Expression
2.3.2 Ability of 18F-FES PET to Assess Heterogeneity of Disease2.3.3 Assess of Response to Endocrine Therapy; 2.3.4 Application of 18F-FES PET in Non-breast Tumor; References; 3: Using 18F-FDG PET/CT to Diagnose and Treat Non-small Cell Lung Cancer; 3.1 Overview; 3.2 Using 18F-FDG PET/CT to Diagnose Non-small Cell Lung Cancer; 3.2.1 Diagnosing Primary Non-small Cell Lung Cancer; 3.2.2 Identifying the TNM Stage; 3.2.2.1 Nodal Metastasis; 3.2.2.2 Distant Metastasis; 3.2.2.3 Bone Metastasis; 3.2.2.4 Brain Metastasis; 3.2.2.5 Adrenal Metastasis; 3.2.2.6 Liver Metastasis
3.2.2.7 Pleural Involvement3.2.3 Identifying the Recurrence of Lung Cancer and Restaging; 3.2.3.1 Diagnosis of NSCLC Recurrence; 3.2.3.2 Surveillance of NSCLC Recurrence; 3.2.3.3 Future Perspectives; 3.3 18F-FDG PET/CT for Non-small Cell Lung Cancer Therapy; 3.3.1 Auxiliary Precise Radio-/Chemotherapy; 3.3.2 Curative Effect Evaluation; 3.3.3 Effect of Treatment Response Assessed by 18F-FDG PET/CT on Patient Management; References; 4: Clinical Application of 18F-FDG PET/CT in Lymphoma; 4.1 Introduction; 4.1.1 Epidemiology of Lymphoma; 4.1.2 Clinical Features of Lymphoma; 4.1.3 Diagnosis of Lymphoma
1.3.3 Clinical Utility of 18F-FDG PET/CT ScanningReferences; 2: Clinical Utility of PET/CT in Breast Cancer Management and Targeted Therapy; 2.1 Introduction; 2.1.1 Epidemiology; 2.1.2 Molecular Subtypes and Gene Expression Tests in Breast Cancer; 2.1.3 Targeted Therapy for Breast Cancer; 2.1.3.1 Anti-HER2 Targeted Therapy; 2.1.3.2 Anti-angiogenic Targeted Therapy; 2.1.3.3 PI3K/AKT/mTOR Pathway Inhibitor; 2.1.3.4 Other Targeted Therapy; 2.2 Clinical Utility of 18F-FDG PET/CT in Breast Cancer; 2.2.1 The Heterogeneity and 18F-FDG Uptake in Breast Cancer
2.2.2 Detection and Differentiation of Primary Breast Cancer2.2.3 Initial Staging; 2.2.3.1 T Staging; 2.2.3.2 Axillary Lymph Node Staging; 2.2.3.3 Staging in Stage II-III Disease and Inflammatory Breast Cancer; 2.2.3.4 Distant Metastases of Breast Cancer; Skeleton Metastases; Extra-skeletal Metastases; 2.2.4 Response Assessment; 2.2.4.1 Early Response Assessment; 2.2.4.2 Post-therapy Evaluation; 2.2.5 Monitoring Recurrence; 2.2.6 Prognostic Assessment; 2.3 Clinical Application of 18F-Fluoroestradiol PET; 2.3.1 18F-FES Uptake and Tumor ER Expression
2.3.2 Ability of 18F-FES PET to Assess Heterogeneity of Disease2.3.3 Assess of Response to Endocrine Therapy; 2.3.4 Application of 18F-FES PET in Non-breast Tumor; References; 3: Using 18F-FDG PET/CT to Diagnose and Treat Non-small Cell Lung Cancer; 3.1 Overview; 3.2 Using 18F-FDG PET/CT to Diagnose Non-small Cell Lung Cancer; 3.2.1 Diagnosing Primary Non-small Cell Lung Cancer; 3.2.2 Identifying the TNM Stage; 3.2.2.1 Nodal Metastasis; 3.2.2.2 Distant Metastasis; 3.2.2.3 Bone Metastasis; 3.2.2.4 Brain Metastasis; 3.2.2.5 Adrenal Metastasis; 3.2.2.6 Liver Metastasis
3.2.2.7 Pleural Involvement3.2.3 Identifying the Recurrence of Lung Cancer and Restaging; 3.2.3.1 Diagnosis of NSCLC Recurrence; 3.2.3.2 Surveillance of NSCLC Recurrence; 3.2.3.3 Future Perspectives; 3.3 18F-FDG PET/CT for Non-small Cell Lung Cancer Therapy; 3.3.1 Auxiliary Precise Radio-/Chemotherapy; 3.3.2 Curative Effect Evaluation; 3.3.3 Effect of Treatment Response Assessed by 18F-FDG PET/CT on Patient Management; References; 4: Clinical Application of 18F-FDG PET/CT in Lymphoma; 4.1 Introduction; 4.1.1 Epidemiology of Lymphoma; 4.1.2 Clinical Features of Lymphoma; 4.1.3 Diagnosis of Lymphoma